ArticleRevista medica del Instituto Mexicano del Seguro Social2024
[Seroprevalence and risk factor for hepatitis C in Nogales, Sonora].
Article in Revista medica del Instituto Mexicano del Seguro Social, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis C Virus (HCV) infection represents a global public health problem, but in Mexico, the Ministry of Health through the National Epidemiological Surveillance System (SINAVE) only reports the distribution of incident cases by state, sex and epidemiological week. Objective: To determine the seroprevalence and factors associated with HCV in beneficiaries of a Family Medicine Unit of the Mexican Social Security Institute (IMSS) in the city of Nogales, Sonora, located on the border between Mexico and the United States. Material and methods: Cross-sectional study that included 145 beneficiaries with rapid HCV antibody test results. Information on risk factors was obtained through direct questioning. To compare groups of reactive and non-reactive patients, Fisher's Exact Test was used and a Logistic Regression model to determine Odds Ratio (OR) values. A P value <0.05 was considered statistically significant. Results: A seroprevalence of 2.8% (95%CI: 0.8 - 6.9) was determined and through the logistic regression model it was found that the history of transfusions (OR: 151.2, 95%CI: 5.9 - 3.858.0) and the use of intranasal drugs (OR: 20.81, 95%CI: 1.3 - 331.3) increase the risk of infection. Conclusions: The seroprevalence of HCV in Nogales is higher than that of the rest of Mexico. Recent studies establish a history of transfusion as a risk factor, but few have explored intranasal drug use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.